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Abstract
Objective To update the clinical practice guidelines for the management of oral mucositis (OM) that were developed by the
Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). This part
focuses on honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents.
Methods A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The body of evidence for each
intervention, in each clinical setting, was assigned an evidence level. The findings were added to the database used to develop the
2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, one of the following guidelines were determined:
Recommendation, Suggestion, No Guideline Possible.
Results A total of 78 papers were identified within the scope of this section, of which 49 were included in this review and merged
with nine publications that were reported in the previous guidelines update. A new Suggestion was made for honey (combined
topical and systemic delivery) for the prevention of OM in head and neck cancer patients receiving radiotherapy with or without
chemotherapy. A new Suggestion clarified that chewing gum is not effective for the prevention of OM in pediatric patients with
hematological or solid cancer treated with chemotherapy. No guideline was possible for other interventions.
Conclusions Numerous natural products and herbal remedies were studied for the management of OM. Of the agents reviewed in
this systematic review, a guideline in favor was made for honey (combined topical and systemic), while a guideline against was
made for chewing gum. Additional research is warranted to clarify the potential of other interventions.
Keywords Oralmucositis . Cancer . Management . Natural . Traditional . Complementary . Herbal
Introduction
Among all cancer treatment toxicities, oral mucositis (OM) is
a common and significant complication. It is frequently ob-
served in head and neck (H&N) cancer patients undergoing
radiotherapy (RT) with or without concomitant chemotherapy
(CT) and in patients undergoing hematopoietic stem cell trans-
plantation (HSCT) [1]. Clinically, it manifests as erythema
and/or ulcerations involving the non-keratinized oral mucosa,
causing severe pain and/or dysphagia, and may result in treat-
ment breaks and prolonged hospitalization.
"In the search for OM prevention, treatment, or palliation, a
broad variety of natural remedies have been suggested. For
many generations, natural remedies have been used for the
management of oral ulcerations in various cultures across
the world. Unlike synthetic drugs, natural remedies are
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generally perceived to have fewer side effects and are there-
fore attractive as potential therapies. Patient-based access to
these products in resource-restricted geographic regions may
be an additional advantage as well.
The Muco s i t i s S t udy Group (MSG) o f t h e
Multinational Association of Supportive Care in Cancer/
International Society of Oral Oncology (MASCC/ISOO)
has published clinical practice guidelines for the manage-
ment of OM [2–4]. In the 2014 guidelines update, the
Natural and Miscellaneous section concluded the system-
atic review with two guidelines regarding honey, herbal
compounds, saliva stimulants/inhibitors, probiotics, and
miscellaneous agents: (1) a suggestion against the use of
systemic pilocarpine administered orally for the preven-
tion of OM associated with RT for H&N cancer and in
patients receiving high-dose chemotherapy, with or with-
out total body irradiation, prior to HSCT; (2) a suggestion
against the use of systemic pentoxifylline administered
orally for the prevention of OM in patients undergoing
HSCT. No guideline was possible for any other agents
[5,6]. The aim of this systematic review was to review
newly reported evidence for the efficacy of natural and
miscellaneous agents for the prevention and/or treatment
of OM and update the clinical practice guidelines.
In the first part of this systematic review, we focused on the
efficacy of vitamins, minerals, and nutritional supplements for
the management of OM [7]. This paper includes studies on
honey, herbal compounds, saliva stimulants/inhibitors,
probiotics, and miscellaneous agents.
Methods
The methods are described in detail in Ranna et al. [8] Briefly,
a literature search for relevant papers indexed in the literature
from January 1, 2011 to June 30, 2016 was conducted using
PubMed/Web of Science/EMBASE, with papers selected for
review based on defined inclusion and exclusion criteria.
Papers were reviewed by two independent reviewers
and data were extracted using a standard electronic form.
Studies were scored for their level of evidence (LoE)
based on Somerfield criteria [9] and flaws were listed
according to Hadorn criteria [10]. A well-designed study
was defined as a study with no major flaws per the
Hadorn criteria.
Findings from the reviewed studies were integrated into
guidelines based on the overall level of evidence for each
intervention. Guidelines were classified into 3 types:
Recommendation, Suggestion, and No Guideline Possible.
Guidelines were separated based on (1) the aim of the in-
tervention (prevention or treatment of mucositis); (2) the treat-
ment modality (RT, CT, RT-CT, or high-dose conditioning
therapy for HSCT); and (3) the route of administration of the
intervention.
The list of intervention keywords used for the literature
search of this section are detailed in the Methods paper [8].
Results
A total of 2653 papers were identified in the literature search:
1863 from PubMed and 790 fromWeb of Science. After care-
ful assessment of the abstracts, 2563 articles were excluded
due to repetition across databases, non-clinical studies, meta-
analyses and reviews. Three additional papers were trans-
ferred from other sections of the guidelines update leading to
a total of ninety-three articles. After review of the full papers,
6 were moved to other sections, and 9 were excluded based on
inclusion/exclusion criteria. A total of 78 papers were includ-
ed in this section. Of them 49 were included in this paper (part
2) (Fig. 1), while 29 papers were included in part 1 [7]. These
49 publications describe 26 various interventions that fall
within the scope of honey, herbal compounds, saliva stimu-
lants/inhibitors, probiotics, and miscellaneous agents. These
papers were merged with 9 publications that were reviewed in
the previous guidelines update.
Honey
Honey has been reported to be effective in promoting wound
healing when applied as a dressing [11]. The wound healing
effect is considered to be primarily mediated by the low-level
hydrogen peroxide generation. Interestingly, compared with
diluted honey, full-strength honey has a lower glucose oxidase
activity, and thus lower level of hydrogen peroxide generation
[12]. There are also non-hydrogen peroxide phytochemical
mechanisms which appear to be involved in wound healing.
In addition, honey has anti-microbial properties which may be
beneficial to prevent secondary infection [13].
Honey (topical) – H&N - RT or RT-CT – prevention
Guideline: No guideline possible (LoE II)
Overall, in the H&N cancer patient population, there were 4
RCTs for topical honey [Table 1] [14–17], Two of these RCTs
demonstrated that honey was effective in preventing OM as-
sociated with RTor RT-CT [16,17]; however, these RCTs had
a small sample size. Therefore, No Guidelines Possible.
Interestingly, the two RCTs that reported honey is ineffective
in preventing radiation-association OM were using Manuka
honey.
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Honey (combined topical-systemic) – H&N – RT or RT-CT –
prevention
Guideline: Suggestion (LoE III)
Honey (combined topical application and systemic adminis-
tration) is suggested for the prevention of OM in H&N cancer
patients treated with either RT or RT-CT.
There is consistent evidence that topical application com-
bined with systemic administration of honey is beneficial in
preventing OM in H&N cancer patients treated with either RT
or RT-CT [Table 1] [18–23]. Since some of these RCTs had a
mixed patient population (RT and RT-CT), small sample size,
and different sources for the honey, only a Suggestion can be
made for the present guideline update.
Likewise, a single study had equivocal results as statistical
significance was not reported [20]. Of note, there was an ad-
ditional RCT comparing a combined protocol of honey,
benzydamine, and nystatin with a control group that received
benzydamine and nystatin only [24]. This latter RCT did not
contribute to our analysis because the patient population was
not clearly defined.
Two RCTs compared honey with another active agent
and are considered comparator studies [25,26]. One
RCT compared topical honey with topical lidocaine
and found honey to be superior in reducing the OM
severity in patients with H&N cancer [25]. In another
RCT, honey was applied to prevent OM in an unspec-
ified group of cancer patients treated with CT [26]. This
study included 3 arms comparing honey with a mix of
honey and caffe ine , and wi th s teroids (8 mg
betamethasone) [26], and found that the combined hon-
ey and caffeine had the greatest reduction in OM
severity.
The source of the honey differed between these stud-
ies: “natural” honey [16,19], royal jelly [17,24], honey
extracted mainly from the tea plant, Camellia sinensis
[18], honey extracted from Thymus and Astragale in the
Alborz mountains [21], honey extracted from the west-
ern Ghats forests [25], honey extracted from the clover
plant Trifolium alexandrenum [22], or unspecified
[20,23].
No data were reported regarding dental caries in the studies
about honey-based protocols for the prevention of OM.
Fig. 1 Article flow chart
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Honey (topical) – hematologic cancer – CT – treatment
Guideline: No guideline possible (LoE III)
This systematic review found a single RCT on honey as
a treatment for OM among pediatric patients with he-
matologic malignancies treated with CT [27]. This study
demonstrated that topical honey was effective in reduc-
ing the duration of OM but not its severity. Since there
is a single RCT in this clinical setting, the guideline
category is No Guideline Possible.
Honey (topical) – hematologic or solid cancer – CT –
prevention
Guideline: No guideline possible (LoE III)
A RCT reported on honey for the prevention of OM in
a mixed patient population of hematologic malignancies
and solid cancers treated with CT [28]. This RCT re-
ported that honey was effective to reduce OM severity.
Considering the limited evidence, as well as the lack of
placebo and blinding in this study, no guideline is
possible.
Propolis
Propolis is a natural wax-like resinous substance collect-
ed by honey bees from the tree buds or other botanical
sources such as poplar, willow, birch, elm, alder, beech,
conifer, and horse-chestnut trees [29]. Propolis is used
by Western and European honeybees as a building ma-
terial in the hive [29]. The chemical composition of
propolis varies and depends on the geographical area,
time of collection, seasonality, illumination, altitude,
and food availability during propolis [29].
Propolis has been used throughout history as a natu-
ral medicine [30]. Its antibacterial, antiseptic, anti-in-
flammatory, anti-fungal, anesthetic, and healing proper-
ties have been reported [30].
Propolis (topical) – hematologic or solid cance – CT –
treatment
Propolis (topical and systemic) – H&N cancer – RT –
prevention
Propolis (topical) – H&N cancer – CT – treatment
Guideline: No guideline possible (LoE III)
Each of the above categories had a single, small RCT
[31–33] and an additional cohort study was reported for
one of these categories (Table 2) [34]. This evidence
was insufficient to determine a guideline for any of
these categories.
Traumeel
Traumeel is a homeopathic intervention used to treat a
variety of conditions related to inflammation. It con-
tains several medicinal plants and minerals in very
low concentrations: Arnica montana , Calendula
officinalis, Atropa belladonna, Aconitum napellus,
Bellis perennis, Hypericum perforatum, Echinacea
angus t i fo l ia , Echinacea purpurea , Symphytum
o f f i c i n a l e , Mat r i c a r i a chamom i l l a , Ach i l l e a
millefolium, Mercurius solubilis hahnemanni [35].
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Traumeel (topical and systemic) – hematologic cancer
(pediatric) – HSCT – prevention
Traumeel (topical and systemic) – H&N cancer – RT or RT-CT –
prevention
Guideline: No guideline possible (LoE II and III, respectively)
Two RCTs assessed traumeel as a preventive therapy for OM
in HSCT pediatric patients [Table 3] [35,36]. Both studies
instructed the patients to swish and swallow. These studies
presented conflicting evidence, therefore no guideline is
possible.
Another comparative study was performed in H&N cancer
patients treated with either RT or RT-CT [37]. This study re-
ported that traumeel was not effective to prevent OM. Due to
the limited evidence, no guideline is possible in this setting
either.
Saliva stimulation
Saliva contains mucosal protective compounds that are vital
for the oral health [38]. Among these salivary proteins are
growth factors such as epidermal growth factor (EGF) and
fibroblast growth factor (FGF) that promote wound healing
and tissue repair. Animal models have shown delayed oral
mucosal wound healing when salivary glands were mechani-
cally obstructed, with the connective tissue being much more
sensitive to lack of saliva than the epithelium [39]. Therefore,
it has been suggested that any decrease in salivary flow may
predispose the oral cavity to cytotoxic damage, whereas in-
creasing salivary flow may support mucosal integrity and
healing.
Chewing gum is a simple and inexpensive method to in-
crease salivary production by up to 10-fold [40]. Therefore, it
is postulated that chewing a gum may be beneficial in the
management of OM. Other modalities that increases the oral
cavity moistening, such as electrostimulation of the salivary
glands or production of an artificial humid climate, may work
in a similar way.
Chewing gum – hematologic/solid cancer (pediatric) – CT –
prevention
Guideline: Suggestion (against) (LoE III)
Chewing gum is not suggested for the prevention of OM in
pediatric patients with hematological or solid cancer treated
with CT.
This review identified 2 large RCTs assessing the potential
of chewing gum for the prevention of OM in a mixed patient
population of hematologic cancers and solid tumors [Table 4]
[41,42]. Both studies were in pediatric patients and reported
no difference between the treatment and control groups in
regard to the reduction of OM severity. In one RCT, the
chewing gum was compared with oral care alone [42] and in
the second RCT, a combination of chewing gum and “magic
mouthwash” was compared with “magic mouthwash” alone
[41]. Considering the consistent evidence from 2 RCTs, a
Suggestion against chewing gum was made.
Artificial moistening – Hematologic cancer – HSCT –
prevention
Artificial humidification – H&N cancer – RT or RT-CT –
prevention
Guideline: No guideline possible (LoE III)
A single RCT was found for chewing gum in patients un-
dergoing HSCT and reported that it was not effective in
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preventing OM [Table 4] [43]. Interestingly, this RCT includ-
ed another experimental group in which patients were treated
with electrostimulation to increase saliva secretion. However,
the study sample was small and the data are limited [43].
Another RCT studied the efficacy of artificial humid-
ification in H&N cancer patients treated with either RT
or RT-CT was published [Table 4] [44]. This study con-
cluded that humidification was beneficial for the preven-
tion of OM. Blinding was not applied in the artificial
humidification study; however, it is understandable that
it is impossible to blind the patient to this treatment
modality [44]. Due to the limited data, no guideline is
possible.
N-acetyl cysteine (NAC) – hematologic cancer – HSCT –
prevention
Guideline: No guideline possible (LoE II)
Asingle RCT evaluated the effectiveness of intravenous
N-acetyl cysteine (NAC) for the prevention of OM in
hematologic cancer patients undergoing HSCT [Table 4]
[45]. The incidence of severe OM (grades 3–4) was
significantly lower and the mean duration of OM was
significantly shorter in the NAC group compared with
the control group. This evidence did not meet the
threshold to determine a guideline.
Curcumin
Curcumin has antioxidant, free-radical scavenging, and
anti-inflammatory properties and has been used in tradi-
tional natural herbal medicine for management of
wound healing and burns [46]. Furthermore, curcumin
was reported to have anti-tumor properties [47].
Curcumin is obtained from the rhizome of Curcuma
longa, a member of the Zingiberaceae family.
Curcumin (topical) – H&N cancer – RT – treatment
Guideline: No guideline possible (LoE III)
A single RCT investigated curcumin in H&N cancer
patient treated with RT [Table 5] [48]. This small
RCT compared Curcuma longa gel with placebo and
found it to be effective for reducing the severity of
OM. Another RCT in an undefined cancer population
compared Indian turmeric combined with honey to a
control group that received no treatment [49].
Considering the limited information about the patient
population, it is impossible to align these data to any
specific clinical setting or to conclude about the efficacy
of turmeric.
Two comparator RCTs were conducted in H&N cancer
patients. The first RCT compared turmeric with povidone io-
dine in patients treated with RT or RT-CT and found turmeric
to be effective in preventing OM [50]. The second RCT
Table 4 Studies reported for saliva stimulants, overall level of evidence, and guideline determination
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compared topical curcumin 0.004% mouthwash with 0.2%
chlorhexidine for the treatment of established RT-CT induced
OM [51]. Since these studies did not use a placebo group, they
were not used for this analysis of curcumin efficacy.
Hangeshashinto (TJ14)
Hangeshashinto is a traditional Japanese herbal medi-
cine. It is a mixture of seven herbs including pinellia
tuber, scutellaria root, glycyrrhiza, jujube, ginseng, proc-
essed ginger, and Coptis rhizome [52]. It reduces the
level of prostaglandin E2 and affects the cyclooxygen-
ase activity in oral keratinocytes in hamsters [53]. These
properties were the basis for the hypothesis that
Hangeshashinto may prevent OM.
Hangeshashinto (topical)– solid cancer – CT – prevention
Guideline: No guideline possible (LoE II)
This review identified 2 RCTs which assessed topical
Hangeshashinto for the prevention of OM in patients with
gastric cancer, and presented opposing conclusions
[Table 5] [52,54]. Both studies used 2.5 g in 50 mL water
three times a day. Considering the conflicting results, no
guideline was possible in this clinical setting.
Hangeshashinto was also used in a comparative study
in H&N cancer patients to prevent OM associated with
either RT or RT-CT [Table 5] [55]. The study reported
that Hangeshashinto was effective in reducing the sever-
ity of OM and improved the completion rate of CT
cycle. Due to limited evidence, no guideline is possible
for this category.
Chamomile
Chamomile is one of the most popular medicinal
p lan ts in the wor ld due to i t s assumed ant i -
inflammatory properties. Its anti-inflammatory activi-
t i e s a r e m e d i a t e d b y t h e i n h i b i t i o n o f
lipopolysaccharide-induced prostaglandin E [2] release
and by reduction of cyclooxygenase (COX)-2 enzyme
activity. Interestingly, chamomile does not affect the
levels of COX-1 [56,57]. Chamomile was also report-
ed to have antibacterial and anti-fungal properties
[58].
Chamomile (topical) – solid cancer – CT – prevention
Guideline: No guideline possible (LoE III)
A RCTwas identified about chamomile for the preven-
tion of OM in patients with solid cancer treated with
CT [Table 5] [59]. The chamomile was delivered as
ice chips and was compared to a control group that
wa s t r e a t e d w i t h i c e ch i p s on l y. Th i s RCT
Table 6 Studies reported for probiotics and miscellaneous agents, overall level of evidence, and guideline determination
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demonstrated that chamomile was effective in reduc-
ing OM severity and in relieving OM-associated pain.
This RCT is added to a previously reported RCT inves-
tigating chamomile in a similar clinical setting that also
reported no benefit [58]. Due to conflicting evidence, no
guideline was possible.
Chamomile (topical) – hematologic cancer – HSCT –
prevention
Guideline: No guideline possible (LoE III)
Topical chamomile was studied for the prevention of OM
in an additional clinical setting–patients undergoing
HSCT [60 ] . Th i s s t udy compa red 3 dose s o f
Chamomilla recutita extract (0.5%, 1%, and 2%) with
standard of care consisting of self-oral hygiene and
0.12% CHX. The authors reported that chamomile 1%
extract significantly reduced the severity and duration of
OM. Due to limited evidence no guideline was possible.
Other herbal remedies
A variety of herbal remedies were reported for the pre-
vention or treatment of OM since the previous guide-
lines update [Table 5]. This includes pycnogenol [61],
olive leaf [62], Kangfuxin [63], Camelia Sinensis leaf
and and Palmitoyil hydrolyzed wheat protein (Baxidil
Onco) [64], clove-based herbal compound [65],
Yashtimadhu ghrita (processed ghee)/Licorice [66],
Calendula [67], and Yarrow plant (also called Achillea
millefolium) [68]. Each intervention had a single RCT.
Lower levels of evidence were published for date palm
pollen [69], mixed compound based on Lapacho and
hyaluronic acid, green tea, Erisimo, propolis, Marigold,
Plantain, and Mauve (OraSol Plus) [70], and compound
based on Vaccinium myrtillus (bilberry), Macleaya
cordata fruits, and Echinacea angustifolia roots
Table 7 Interventions for which the evidence and guideline are unchanged, based on existing literature (Adapted fromYarom 2013, Jensen 2013) [5,6]





P Aloe vera* Systemic (PO) H&N cancer RT or RT-CT NGP
P Quing Wei San or Yu Nu Jian Topical Hematol. NS NGP
P Indigowood root Topical & systemic H&N cancer RT or RT-CT NGP
T MF5232 Systemic (PO) H&N cancer RT-CT NGP
P Rhodiola algida Systemic (PO) Solid cancer CT NGP
T Compound collagen, amino-acids and sodium
hyaluronate
Topical H&N cancer, hematol. cancer, solid
cancer
RT or RT-CT or
CT
NGP
P Wobe-mugos E Systemic (PO) H&N cancer RT NGP
P Manuka & kanuka oils Topical & systemic H&N cancer RT NGP
P Allopurinol Systemic (PO) Hematol. cancer, solid cancer CT NGP
P Allopurinol Topical Solid cancer CT NGP
P Papayor Topical H&N cancer RT NGP
P RT (timing) NA H&N cancer RT NGP
P Pilocarpine Systemic (PO) H&N cancer RT Suggestion
against
P Pilocarpine Systemic (PO) Hematol. cancer HSCT Suggestion
against
P Propantheline Systemic (PO) Hematol. and solid cancers HSCT NGP
P Bethanechol Systemic (PO) H&N cancer RT
P Tetrachlorodecaoxide Systemic (PO) Hematol. and solid cancers CT NGP
P PTX Systemic (PO) Hematol. cancer HSCT Suggestion
against
P PTX Systemic (IV) Hematol. cancer HSCT NGP
P PTX Systemic (PO) Solid cancer CT NGP
P prevention, T treatment, H&N head and neck, RT radiotherapy, RT-CT radiochemotherapy, Hematol. hematologic, CT chemotherapy, HSCT hema-
topoietic stem cell transplantation, NGP no guideline possible, PTX pentoxifylline, PO per os, IV intravenous
*A comparator RCTwas published but was not contributory to the efficacy analysis–aloe vera vs benzydamine [96]
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(Samital) [71]. Due to the limited evidence, no guide-
line is possible for these compounds.
Probiotics and miscellaneous agents
Protean interventions were assessed for either prevention or
treatment of OM [Table 6]. Two studies on probiotics were
focused on lactobacillus and lactococcus that were adminis-
tered either systemically or topically [72,73]. Both studies
showed efficacy in preventing OM in H&N cancer patients.
Considering the limited data for each of these probiotics, no
guideline is possible.
Miscellaneous agents that were tested for the management
of OM and included in this systematic review are
Phenylbutyrate gelformulation mouthwash [72–74], phenyto-
in [75], oral beta-glucan [76] and platelet gel supernatant [77],
and ankaferd hemostat [Table 6] [78]. No guideline was pos-
sible for any of these interventions.
Interventions for which evidence was reported prior to
2011 (addressed in the previous guidelines), and no new evi-
dence was reported since are listed briefly as summarized in
the 2013 Guidelines Update [Table 7].
Discussion
Herbal remedies have been used for centuries for the
healing of numerous conditions in different cultures
worldwide [79]. They are the imprint of the local cultures,
unique regional vegetation, and ancient medicine knowl-
edge. Herbal remedies are becoming more accessible to a
larger community as global communication and interest in
alternative medicine increases. With modernized industri-
al techniques, these agents are available for larger popu-
lations. This manuscript covers natural agents, probiotics,
and modalities that are affecting the moistening in the
mouth and a group of miscellaneous agents. Two new
guidelines were made based on this systematic review: a
Suggestion in favor for honey, and a Suggestion against
chewing gum.
Honey, as a combination protocol of topical and systemic
administration, is suggested to prevent OM in patients with
H&N cancer treated with RT or RT-CT [18–23]. This new
guideline is based on several RCTs showing positive effects
for honey. However, since some of these RCTs had a mixed
patient population, small sample size, and different sources for
the honey, the guidelines can only be confined to a
Suggestion. Notably, both RCTs studying topical Manuka
honey were negative, and it is unclear if a combined topical
and systemic application ofManuka honey will be effective in
preventing OM in H&N cancer patients.
Importantly, honey has a cariogenic effect and it adheres to
the teeth. . Although the prevention of OM is limited for the
duration of the RT, if the honey is applied repeatedly on a daily
basis for a longer period, such deleterious effects may occur
[80,81] Accordingly, patients who are applying honey to pre-
vent OM should be on a strict oral hygiene program to prevent
dental caries [82].
The systematic review yielded a new guideline for
chewing gum. Based on the evidence available from 2
RCTs in pediatric patients, a suggestion against the use
of chewing gum was made for the prevention of OM in
patients with hematologic or solid cancer treated with CT.
This guideline does not preclude the use of chewing gum
for any other purpose: saliva production, flavor, refresh-
ment, or simply joy. This guideline reflects the fact that
chewing gum will not prevent OM in this clinical setting.
Other changes in this section compared with the 2013
guidelines update include identifying evidence for new inter-
ventions (propolis), artificial humidification, or for a new clin-
ical setting (curcumin, traumeel, Hangeshashinto).
Unfortunately, this new evidence did not culminate into a
guideline.
The scope of “miscellaneous” treatments for the man-
agement of OM may extend to medical devices, such as
appliances to reduce RT-associated OM [83,84]. The
group felt that this topic would benefit from a dedicated
systematic review, although it was touched on in the pre-
vious guidelines update [5]. Likewise, impact of cancer
treatment modality and radiation technique on outcomes
and toxicity of patients are not included in this systematic
review as OM was a secondary endpoint. Rarely, studies
on the modification to the cancer therapy protocol ad-
dressed OM as the primary endpoint [85–87].
Several studies were published since the cut-off date of
this literature review, which refers to propolis, honey,
Glycyrrhiza aqueous extract and licorice. Propolis was
studied in a RCT in breast cancer patients receiving doxo-
rubicin and cyclophosphamide. The results showed that
propolis plus sodium bicarbonate was significantly more
effective than sodium bicarbonate alone in preventing OM
[88]. As this study reports about a clinical setting that was
not reported previously, this is considered to be initial
information that needs confirmation in the future.
Propolis was also studied as part of a mixture of 4 natural
agents: propolis, Aloe vera, calendula, and chamomile
[89]. In this RCT in H&N cancer patients receiving RT,
the mixture was reported to be superior to placebo in
preventing OM. A recent RCT investigated honey to pre-
vent OM in a single-blinded design [90]. This study con-
cluded that honey was effective in preventing OM in pa-
tients with leukemia treated with CT; however, consider-
ing the variation in the mode of application, and the small
sample size, the collective evidence about honey in this
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clinical setting did not cross the threshold for a guideline.
Glycyrrhiza aqueous extract was studied in a single small
RCT, and showed positive results. This evidence was too
limited to set a guideline [91]. Licorice in mucoadhesive
vehicle was reported to be as effective as triamcinolone
acetonide in reducing OM severity in H&N cancer pa-
tients treated with RT only [92]. As this RCT was de-
signed as a comparator study without a placebo arm, the
results are not contributory to the efficacy analysis in this
study.
In summary, the MASCC/ISOO guideline update sug-
gests applying honey, combined topically and systemical-
ly, for the prevention of OM in H&N cancer patients
treated with either RT or RT-CT. Chewing gum is not
suggested for the prevention of OM in pediatric patients
with hematological or solid cancer treated with CT. These
guidelines are subject to further updates pending results of
future published studies.
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